Hepatocellular Carcinoma
Advertisement
While immunotherapy paired with VEGF inhibitors are considered first-line options, they only provide modest efficacy.
Dr. Luo describes the performance of the two-fusion gene + α-fetal protein logistic regression model.
Dr. Luo explains the potential benefits of machine learning for patients with hepatocellular carcinoma.
While TACE is a common treatment for HCC, the procedure alone is associated with unsatisfactory survival benefits.
Dr. Luo and colleagues identified a need for increased screening measures for patients with HCC.
[68Ga]Ga-RYZ-GPC3 shows high specificity in detecting hepatocellular carcinoma, outperforming conventional imaging.
Researchers conducted a comprehensive analysis to determine the association between HCC disease stage and prognosis.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
Atezolizumab/bevacizumab and lenvatinib have both shown efficacy as first-line treatments for hepatocellular carcinoma.
The latest guideline update includes recommendations for first-, second-, and third-line therapy options.
Ablative therapy is an important treatment option for achieving a cancer-free state as HCC rates continue to rise.
Researchers found that patients with diabetes and higher alpha-fetoprotein had decreased OS rates.
In patients with HCC, a high CD8 and low TIM3 expression is linked to better OS than PD-1/PD-L1.
Dr. Elizabeth Conner offers insight on how DCP can be utilized as a biomarker for treatment response in patients with HCC.
A new report detailed the results of the LEAP-002 study following 12 months of additional follow-up.
An analysis of demographic, clinical characteristics, and treatment patterns for HCC for defining early-stage disease.
Dr. Julien Calderaro explains the potential of AI to serve as a biomarker of sensitivity to atezolizumab plus bevacizumab.
Drs. Llovet and Finn consider how LEAP-002 adds to the debate around IO/VEGF, IO/IO, and IO/TKI for aHCC.
Drs. Llovet and Finn provide a high-level understanding of LEAP-002, looking at lenvatinib/pembrolizumab for 1L aHCC.
The CRAFITY score is based on C-reactive protein and serum AFP in immunotherapy to predict prognosis in patients with HCC..
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.